Alkermes' (ALKS) settlement with Teva Pharmaceuticals (TEVA) regarding a generic Lybalvi largely offsets downward pricing adjustments for alixorexton following competitor pricing, RBC Capital Markets said in a Thursday note.
Under the settlement, Teva is barred from launching its generic version until November 2039, or May 2040 under certain circumstances, removing prior modeled assumptions of generic competition starting in 2032.
RBC updated its model to reflect continued Lybalvi revenues through 2035 with peak sales expected at $722 million, compared with its prior guidance of $213 million.
Concurrently, following Takeda Pharmaceutical's (TAK) orexin pricing announcement of $16,500 per month across all three doses, for an annualized list price of $198,000, RBC lowered its expected price for alixorexton to about $288,000 annually from $350,000.
The firm now models 2035 alixorexton sales of $2.7 billion, down from its earlier expectation of $3.3 billion.
RBC Capital Markets maintained its outperform rating on Alkermes and a $57 price target.
Price: 46.67, Change: -0.31, Percent Change: -0.66
Comments